Back
Full-text
Journal article

Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer.

  • Wang Y 1] Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK. [2].
  • McKay JD 1] International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France. [2] [3].
  • Rafnar T deCODE Genetics, Amgen, Reykjavik, Iceland.
  • Wang Z Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Timofeeva MN International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Broderick P Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.
  • Zong X Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Laplana M Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wei Y Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.
  • Han Y Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA.
  • Lloyd A Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.
  • Delahaye-Sourdeix M International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Chubb D Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.
  • Gaborieau V International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Wheeler W Information Management Services, Inc., Rockville, Maryland, USA.
  • Chatterjee N Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Thorleifsson G deCODE Genetics, Amgen, Reykjavik, Iceland.
  • Sulem P deCODE Genetics, Amgen, Reykjavik, Iceland.
  • Liu G Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.
  • Kaaks R 1] Division of Cancer Epidemiology, DKFZ, Heidelberg, Germany. [2] Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Henrion M Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.
  • Kinnersley B Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK.
  • Vallée M International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • LeCalvez-Kelm F International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Stevens VL Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
  • Gapstur SM Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA.
  • Chen WV Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Zaridze D Institute of Carcinogenesis, Russian N.N. Blokhin Cancer Research Centre, Moscow, Russia.
  • Szeszenia-Dabrowska N Department of Epidemiology, Institute of Occupational Medicine, Lodz, Poland.
  • Lissowska J The M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Rudnai P National Institute of Environmental Health, Budapest, Hungary.
  • Fabianova E Regional Authority of Public Health, Banská Bystrica, Slovak Republic.
  • Mates D National Institute of Public Health, Bucharest, Romania.
  • Bencko V 1st Faculty of Medicine, Institute of Hygiene and Epidemiology, Charles University in Prague, Prague, Czech Republic.
  • Foretova L Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Janout V Palacky University, Olomouc, Czech Republic.
  • Krokan HE Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
  • Gabrielsen ME Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
  • Skorpen F Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Vatten L Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Njølstad I Department of Community Medicine, University of Tromsø, Tromsø, Norway.
  • Chen C Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Goodman G Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Benhamou S INSERM U946, Paris, France.
  • Vooder T Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia.
  • Välk K Department of Biomedicine, University of Bergen, Bergen, Norway.
  • Nelis M 1] Estonian Genome Center, Institute of Molecular and Cell Biology, Tartu, Estonia. [2] Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland.
  • Metspalu A Estonian Genome Center, Institute of Molecular and Cell Biology, Tartu, Estonia.
  • Lener M Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  • Lubiński J Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  • Johansson M International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Vineis P 1] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK. [2] Unit of Molecular and Genetic Epidemiology, HuGeF Foundation, Torino, Italy.
  • Agudo A Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, Barcelona, Spain.
  • Clavel-Chapelon F 1] INSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women's Health Team, Villejuif, France. [2] Université Paris Sud, UMRS 1018, Villejuif, France. [3] Institut Gustave Roussy, Villejuif, France.
  • Bueno-de-Mesquita HB 1] Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK. [2] National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [3] Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.
  • Trichopoulos D 1] Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. [2] Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [3] Hellenic Health Foundation, Athens, Greece.
  • Khaw KT University of Cambridge School of Clinical Medicine, Clinical Gerontology Unit, Addenbrooke's Hospital, Cambridge, UK.
  • Johansson M Department of Radiation Sciences, Umeå Universitet, Umeå, Sverige, Sweden.
  • Weiderpass E 1] Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. [2] Department of Research, Cancer Registry of Norway, Oslo, Norway. [3] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [4] Samfundet Folkhälsan, Helsinki, Finland.
  • Tjønneland A Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Riboli E Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, UK.
  • Lathrop M Centre d'Etude du Polymorphisme Humain (CEPH), Paris, France.
  • Scelo G International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Albanes D Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Caporaso NE Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Ye Y Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Gu J Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wu X Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Spitz MR Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
  • Dienemann H 1] Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany. [2] Department of Thoracic Surgery, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany.
  • Rosenberger A Department of Genetic Epidemiology, University of Göttingen, Göttingen, Germany.
  • Su L Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.
  • Matakidou A Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.
  • Eisen T 1] Department of Oncology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK. [2] Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
  • Stefansson K deCODE Genetics, Amgen, Reykjavik, Iceland.
  • Risch A 1] Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany. [2] Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
  • Chanock SJ Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA.
  • Christiani DC Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA.
  • Hung RJ Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Brennan P International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.
  • Landi MT 1] Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA. [2] [3].
  • Houlston RS 1] Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK. [2] [3].
  • Amos CI 1] Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA. [2] [3].
Show more…
  • 2014-06-02
Published in:
  • Nature genetics. - 2014
Adenocarcinoma
BRCA2 Protein
Carcinoma, Squamous Cell
Case-Control Studies
Checkpoint Kinase 2
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Lung Neoplasms
Meta-Analysis as Topic
Polymorphism, Single Nucleotide
Prognosis
Risk Factors
English We conducted imputation to the 1000 Genomes Project of four genome-wide association studies of lung cancer in populations of European ancestry (11,348 cases and 15,861 controls) and genotyped an additional 10,246 cases and 38,295 controls for follow-up. We identified large-effect genome-wide associations for squamous lung cancer with the rare variants BRCA2 p.Lys3326X (rs11571833, odds ratio (OR) = 2.47, P = 4.74 × 10(-20)) and CHEK2 p.Ile157Thr (rs17879961, OR = 0.38, P = 1.27 × 10(-13)). We also showed an association between common variation at 3q28 (TP63, rs13314271, OR = 1.13, P = 7.22 × 10(-10)) and lung adenocarcinoma that had been previously reported only in Asians. These findings provide further evidence for inherited genetic susceptibility to lung cancer and its biological basis. Additionally, our analysis demonstrates that imputation can identify rare disease-causing variants with substantive effects on cancer risk from preexisting genome-wide association study data.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/138243
Statistics
Document views: 7 File downloads:
  • fulltext.pdf: 0